Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00047476 · ClinicalTrials.gov registry record · Phase 2
D-MPH in the Treatment of Fatigue and Neurobehavioral Function Related to Chemotherapy in Adult Cancer Patients
A Phase 2 study, sponsored by Celgene Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
NCT00047476 is a Phase 2 study that has completed, run by Celgene Corporation. The registered enrollment target is 160 participants.
The verdict
NCT00047476, a Phase 2 study, has completed, sponsored by Celgene Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
Study Summary
To evaluate the efficacy of dexmethylphenidate (d-MPH) in the treatment of chemotherapy-related fatigue in adult cancer subjects.
Interventions
- DRUG dexmethylphenidate(d-mph)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2002-06 |
| Est. Completion | 2004-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00047476
The ClinicalTrials.gov registry entry for NCT00047476 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene Corporation, which has 40 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which dexmethylphenidate(d-mph) is the first listed.
NCT00047476 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00047476 about?
NCT00047476 is a clinical study titled "D-MPH in the Treatment of Fatigue and Neurobehavioral Function Related to Chemotherapy in Adult Cancer Patients". To evaluate the efficacy of dexmethylphenidate (d-MPH) in the treatment of chemotherapy-related fatigue in adult cancer subjects.
What is the current status of trial NCT00047476?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2002-06. Estimated completion is 2004-03.
What interventions are being tested in trial NCT00047476?
The interventions under investigation include: dexmethylphenidate(d-mph) (DRUG).
Who is sponsoring clinical trial NCT00047476?
This trial is sponsored by Celgene Corporation, which has 40 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.